Eiger BioPharmaceuticals (EIGR)

10.52 +0.39 (3.85%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/13/18 *Est.)

Latest Headlines

Form SC 13G Eiger BioPharmaceuticals Filed by: Broadfin Capital, LLC June 14, 2019 4:27 PM - SEC Filing Form 8-K Eiger BioPharmaceuticals For: Jun 11 June 12, 2019 4:33 PM - SEC Filing Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs June 10, 2019 8:00 AM - PR NewsWire Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development June 5, 2019 8:00 AM - PR NewsWire Form 4 Eiger BioPharmaceuticals For: May 30 Filed by: Sachdev Amit May 30, 2019 5:38 PM - SEC Filing Form 3 Eiger BioPharmaceuticals For: Apr 15 Filed by: Sachdev Amit May 30, 2019 5:36 PM - SEC Filing Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference May 30, 2019 8:00 AM - PR NewsWire Form 8-K Eiger BioPharmaceuticals For: May 13 May 17, 2019 4:17 PM - SEC Filing Eiger BioPharmaceuticals (EIGR) COO David Apelian to Step Down May 17, 2019 4:06 PM - StreetInsider Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer May 17, 2019 4:05 PM - PR NewsWire Form 10-Q Eiger BioPharmaceuticals For: Mar 31 May 9, 2019 4:26 PM - SEC Filing Form 8-K Eiger BioPharmaceuticals For: May 09 May 9, 2019 4:19 PM - SEC Filing Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update May 9, 2019 4:01 PM - PR NewsWire Form SC 13G EIGER BIOPHARMACEUTICALS Filed by: Cormorant Asset Management, LP May 3, 2019 4:44 PM - SEC Filing Eiger to Present at ChinaBio® Partnering Forum 2019 April 30, 2019 8:00 AM - PR NewsWire Form 4 Eiger BioPharmaceuticals For: Apr 25 Filed by: Cory David A April 26, 2019 4:56 PM - SEC Filing Form DEFA14A Eiger BioPharmaceuticals April 26, 2019 4:42 PM - SEC Filing Form DEF 14A Eiger BioPharmaceuticals For: Jun 11 April 26, 2019 4:33 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Apr 23 Filed by: Dietz Thomas John April 23, 2019 6:54 PM - SEC Filing Eiger BioPharma (EIGR) PT Lowered to $35 at Wedbush April 23, 2019 4:02 PM - StreetInsider Form 4 Eiger BioPharmaceuticals For: Apr 22 Filed by: Ryali Sriram April 22, 2019 9:35 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Apr 22 Filed by: Dietz Thomas John April 22, 2019 9:35 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Apr 22 Filed by: Patton Stephana Eilene April 22, 2019 9:32 PM - SEC Filing Form 8-K Eiger BioPharmaceuticals For: Apr 17 April 22, 2019 4:37 PM - SEC Filing Form 424B5 Eiger BioPharmaceuticals April 18, 2019 4:35 PM - SEC Filing Pre-Open Stock Movers 04/18: (MBIO) (URI) (CGC) Higher; (ATNM) (SNBR) (TEAM) Lower (more...) April 18, 2019 9:21 AM - StreetInsider Eiger BioPharmaceuticals (EIGR) Prices 4.5M Share Offering at $11/Sh April 18, 2019 5:43 AM - StreetInsider Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock April 17, 2019 10:53 PM - PR NewsWire After-Hours Movers 04/17: (MBIO) (URI) (CGC) Higher; (ATNM) (SNBR) (TEAM) (more...) April 17, 2019 5:49 PM - StreetInsider Form 424B5 Eiger BioPharmaceuticals April 17, 2019 4:08 PM - SEC Filing Eiger BioPharmaceuticals (EIGR) Commences Public Offering of Common Stock April 17, 2019 4:01 PM - StreetInsider Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock April 17, 2019 4:01 PM - PR NewsWire Form 8-K Eiger BioPharmaceuticals For: Apr 12 April 15, 2019 4:17 PM - SEC Filing Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors April 15, 2019 8:00 AM - PR NewsWire Eiger BioPharmaceuticals (EIGR) Reports 36% Durable Virologic Response at 24-Wk Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study April 11, 2019 4:10 PM - StreetInsider Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019 April 11, 2019 4:05 PM - PR NewsWire Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Apelian David March 26, 2019 10:24 AM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Shaffer James P March 26, 2019 10:13 AM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Cory David A March 26, 2019 10:08 AM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Murray Christine March 26, 2019 10:04 AM - SEC Filing Eiger BioPharmaceuticals to Participate in Conferences in April March 26, 2019 8:01 AM - PR NewsWire Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Mayer Eldon C. III March 25, 2019 10:01 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Dietz Thomas John March 25, 2019 9:55 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Glenn Jeffrey S March 25, 2019 9:53 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Loh Evan March 25, 2019 9:51 PM - SEC Filing Form 4 Eiger BioPharmaceuticals For: Mar 21 Filed by: Patton Stephana Eilene March 25, 2019 9:48 PM - SEC Filing Form 3 Eiger BioPharmaceuticals For: Mar 18 Filed by: Patton Stephana Eilene March 25, 2019 9:46 PM - SEC Filing Eiger BioPharmaceuticals (EIGR) Highlights Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2019 Meetings March 25, 2019 1:34 PM - StreetInsider Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 March 25, 2019 1:30 PM - PR NewsWire Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 March 20, 2019 8:01 AM - PR NewsWire Full Article List